| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.35▲ | 0.34▲ | 0.34▲ | 0.78▼ | 1.05▼ |
| MA10 | 0.35▲ | 0.34▲ | 0.34▲ | 1.06▼ | 1.12▼ |
| MA20 | 0.34▲ | 0.34▲ | 0.37▼ | 1.10▼ | 1.20▼ |
| MA50 | 0.34▲ | 0.60▼ | 0.95▼ | 1.15▼ | 1.62▼ |
| MA100 | 0.35▼ | 0.98▼ | 1.08▼ | 1.25▼ | 2.40▼ |
| MA200 | 0.62▼ | 1.07▼ | 1.12▼ | 1.64▼ | 8.04▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.024▲ | 0.031▲ | -0.104▼ | -0.014▼ |
| RSI | 69.414▲ | 27.551▼ | 16.543▼ | 19.147▼ | 27.509▼ |
| STOCH | 96.171▲ | 93.797▲ | 67.515 | 45.301 | 47.402 |
| WILL %R | 0.000▲ | 0.000▲ | -64.230 | -97.371▼ | -97.371▼ |
| CCI | 103.521▲ | 120.629▲ | 33.569 | -167.642▼ | -353.250▼ |
|
Wednesday, April 29, 2026 12:03 PM
By David Bautz, PhD NASDAQ: SNGX READ THE FULL SNGX RESEARCH REPORT Business Update FLASH2 Trial Recommended to Stop for Futility On April 28, 2026, Soligenix, Inc. (NASDAQ: SNGX) announced interim ...
|
|
Tuesday, April 28, 2026 08:06 AM
Soligenix halts its late-stage CTCL trial for futility, forcing a reassessment of its lead drug and future direction. Soligenix (NASDAQ:SNGX) just hit a major setback after its Phase 3 FLASH2 trial ...
|
|
Tuesday, April 28, 2026 06:00 AM
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/04/26 | 0.3301 | 0.35 | 0.3157 | 0.345 | 1,422,135 |
| 29/04/26 | 0.41 | 0.4156 | 0.3281 | 0.338 | 3,810,520 |
| 28/04/26 | 0.6106 | 0.6337 | 0.3701 | 0.4209 | 14,974,636 |
| 27/04/26 | 1.41 | 1.43 | 1.38 | 1.415 | 114,448 |
| 24/04/26 | 1.37 | 1.39 | 1.34 | 1.39 | 61,081 |
| 23/04/26 | 1.36 | 1.385 | 1.33 | 1.37 | 138,216 |
| 22/04/26 | 1.33 | 1.355 | 1.3005 | 1.34 | 159,381 |
| 21/04/26 | 1.41 | 1.43 | 1.32 | 1.34 | 308,452 |
| 20/04/26 | 1.29 | 1.4199 | 1.27 | 1.38 | 904,534 |
| 17/04/26 | 1.18 | 1.25 | 1.17 | 1.25 | 565,982 |
|
|
||||
|
|
||||
|
|